Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexmedetomidine + ketamine + lidocaine
- Development stage
- Unknown
- Lead developer
- National Taiwan University Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Dexmedetomidine + ketamine + lidocaine is a multimodal analgesic combination therapy being evaluated by the National Taiwan University Hospital. This combination leverages the synergistic effects of three distinct pharmacological agents: dexmedetomidine (a highly selective alpha-2 adrenergic agonist), ketamine (an N-methyl-D-aspartate [NMDA] receptor antagonist), and lidocaine (a local anesthetic and systemic sodium channel blocker). The mixture is primarily investigated for its anesthetic-sparing effects and its potential to provide renal protection (reducing the risk of acute kidney injury) in patients undergoing complex procedures such as head and neck cancer surgery with free flap microvascular reconstruction. By targeting multiple pain pathways and reducing the systemic inflammatory response, the combination aims to improve postoperative outcomes and reduce the reliance on high-dose volatile anesthetics and opioids.
- Other names
- dexmedetomidine-ketamine-lidocaine mixtureDKL mixturedexmedetomidine + ketamine + lidocaine mixture
02
Targets
ADRA2B (α2B)NaV (Voltage-gated sodium channels)ADRA2A (α2A)ADRA2C (α2C)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on dexmedetomidine + ketamine + lidocaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexmedetomidine + ketamine + lidocaine.